45.   (Once Amended) A glycopolypeptide comprising between 41 and 400 amino acid that can bind human spermatozoa at a glycopolypeptide concentration below 1 µg/ml and induce an acrosome reaction within one hour upon binding, wherein said glycopolypeptide comprises an amino acid sequence that is at least 54% homologous to the following sequence SEQ ID NO 2:

> SerTrpPheProValGlnGlyProAlaAspIleCysGlnCysCysAsnLysGly
>
> AspCysGlyThrProSerHisSerArgArgGlnProHisValMetSerGlnTrp
>
> SerArgSerValSer,

and wherein the fifth amino acid residue from the carboxyl terminus of said amino acid sequence of said glycopolypeptide is O-glycosylated.

46.   (Once Amended) The glycopolypeptide of claim 45, wherein said glycopolypeptide comprises an amino acid sequence that is at least 75% homologous to the following sequence SEQ ID NO 2:

> SerTrpPheProValGlnGlyProAlaAspIleCysGlnCysCysAsnLysGlyA
>
> spCysGlyThrProSerHisSerArgArgGlnProHisValMetSerGlnTrpSer
>
> ArgSerValSer.

47.   (Twice Amended) The glycoprotein of claim 45, wherein the glycoprotein comprises the following amino acid sequence SEQ ID NO 2:

SerTrpPheProValGlnGlyProAlaAspIleCysGlnCysCysAsnLysGlyAspCysGlyThrPro

SerHisSerArgArgGlnProHisValMetSerGlnTrpSerArgSerValSer.

Remarks

Claims 25-38, 40, and 42-47 are pending. Claims 44-47 have been amended to insert the sequence identification number. The Examiner has stated that claims 44-47 recite SEQ ID NO 1, however, as of entry of the amendment dated February 28, 2001, claims 44-47 recite SEQ ID NO 2.

In response to the restriction requirement, applicants elect Group I with traverse. Applicants respectfully contend for that the Examiner has failed to establish a *prima facie* case that the restriction is proper. As stated in MPEP § 803, "an application may properly be restricted to one of two or more inventions only if they are able to support separate patents and they are either independent or distinct. If the search of the entire application can be made